Qualitest Pharmaceuticals has received approval from the Food and Drug Administration for its Emoquette oral contraceptive.


Qualitest, Emoquette, oral contraceptive, desogestrel and ethinyl estradiol, Ortho-Cept, generic, birth control, Endo, pharmaceutical, Ortho-McNeil














































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Qualitest cleared to market oral contraceptive

March 4th, 2011

HUNTSVILLE, Ala. – Qualitest Pharmaceuticals has received approval from the Food and Drug Administration for its Emoquette oral contraceptive.

The company, acquired late last year by Endo Pharmaceuticals, said Friday that it was cleared by the FDA to market Emoquette (desogestrel and ethinyl estradiol) in 0.15 mg/0.03 mg tablets.

The product is a generic version of Ortho-McNeil Pharmaceuticals' Ortho-Cept contraceptive.

A combination hormone medication, ethinyl estradiol and desogestrel are designed prevent ovulation. The birth control therapy also causes changes in the cervical mucus and uterine lining, making it more difficult for sperm to reach the uterus and for a fertilized egg to attach to the uterus.

Advertisement